Back to top

crispr: Archive

Sundeep Ganoria

CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?

The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, CRSP is yet to record product sales.

VRTXPositive Net Change BEAMNegative Net Change NTLAPositive Net Change CRSPPositive Net Change

Zacks Equity Research

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Editas stock falls as it ends development of reni-cel for SCD and TDT following failed attempts to find a commercial partner. It plans to cut workforce by 65%.

EDITPositive Net Change CTMXPositive Net Change SPRONegative Net Change CSTLNegative Net Change